


# Immuno-oncology publication spotlight: our top recent peer-reviewed journal articles featuring Fortrea oncologists discussing immuno-oncology drug development

## Introduction

Immuno-oncology therapies, also known as cancer immunotherapies, represent a broad class of treatments such as targeted antibodies, tumor-infecting viruses, checkpoint inhibitors and cancer vaccines. The many types of therapeutic agents have been under study for decades and Fortrea has participated in over 290 immuno-oncology trials in just the last five years (2019-2023).



**Fig:** Classification of immuno-oncology agents used in cancer treatment.  
(Ref: Franklin, Platero, Saini, et al. *J Immunother Cancer*. 2022; 10(1): e003231.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756278/>)

Fortrea supports our sponsors with a team of 60 oncologists who employ a collaborative approach, which can result in co-authorship of peer reviewed journal articles based on projects we've supported. In addition, they have contributed to industry knowledge via articles about their own academic and collaborative work. We are proud that our oncology team contributes to the advancement of cancer research in this way. Some of our latest publications relating to immuno-oncology include the following articles.



- 1 **“Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer.”**

*Frontiers in Immunology.*  
June 2024.

“We analyzed biosamples from 8,230 patients with NSCLC, and found distinct genomic and immune microenvironment profiles for tumors of younger patients compared to tumors of older patients, and also males versus females.” Read the article here: <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1413956/full>

- 2 **“Differential impact of lipid profile according to NLR status in patients with advanced cancer treated with immunotherapy.”**

*Immunotherapy.*  
August 2024.

“We analyzed lipid profile in 407 patients with advanced cancer patients treated with immune checkpoints inhibitors and showed a distinct prognostic impact of lipid profile according to according to neutrophil-to-lymphocyte ratio (NLR) value.” Read the article here: <https://doi.org/10.1080/1750743X.2024.2377953>

- 3 **“Immune checkpoint inhibitors in breast cancer: a narrative review.”**

*Oncology & Therapy.*  
March 2023.

“In this overview, we describe the range of adverse events of immunotherapy, including dermatologic, gastrointestinal, hepatic, endocrine, and pulmonary toxicities and their management.” Read the article here: <https://doi.org/10.1007/s40487-023-00224-9>

**4** “Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study.”

*Journal of National Cancer Institutes.*  
April 2023.

“We showed that extending the dosing interval of immune checkpoint inhibitors compared to conventional dosing interval did not increase adverse events, and represents a safe option also outside clinical trials.” Read the article here: <https://doi.org/10.1093/jnci/djad061>

**5** “Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy.”

*Frontiers in Oncology.*  
June 2023.

“We describe the various immune escape mechanisms in the tumor microenvironment (TME). Modern therapies including nanomedicines, ICIs, CAR-Ts, and epigenetic modulation may reprogram the TME and shift the host response into an antitumor response.” Read the article here: <https://doi.org/10.3389/fonc.2023.1200646>

**6** “Prognostic impact of blood lipid profile in patients with advanced solid tumors treated with immune checkpoint inhibitors: a multicenter cohort study.”

*Oncologist.*  
October 2023.

“We have developed a lipid score that identifies subgroups of patients with cancer who benefit from immune checkpoint inhibitors.” Read the article here: <https://doi.org/10.1093/oncolo/oyad273>



See a full list of Fortrea oncology publications starting in 2020.

Fortrea  
Together, exceptional is possible

**LEARN MORE** at [fortrea.com/oncology](https://fortrea.com/oncology)

